Sidira Despoina, Siafaka Angeliki, Chrysikos Dimosthenis, Papadopoulos Georgios, Stratopoulos Epameinondas, Filippou Dimitrios
Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Department of Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Acta Med Acad. 2024 Aug;53(2):155-164. doi: 10.5644/ama2006-124.450.
The deadliest, most dangerous subtype of breast cancer is triple-negative, which lacks treatment targets and accounts for 30% of all breast cancer-related deaths worldwide. TNBC is characterized by the expression of no estrogen, progesterone, or human epidermal growth factor 2 receptors. This suggests that new treatment modalities with fewer adverse effects are required.
The aim of the present study was to investigate the therapeutic potential of selenium compounds as an adjuvant therapy for Triple Negative Breast Cancer (TNBC), either on their own or in conjunction with nutritional supplements and chemotherapy medications.
Using the keywords "selenium" and "triple negative breast cancer", a thorough search was conducted in the PubMed database, yielding 23 articles. The following factors were taken into consideration for inclusion: studies using TNBC cell culture lines or in vivo tumors/specimens; full-text articles from the PubMed database; studies published in the English language; experiments with statistically significant results; and selenium used alone or in combination with other antioxidants or chemotherapy. This led to the evaluation of 13 articles in this review.
The results show that selenium therapy increased the anti-cancer drug's effects and produced tumor cytotoxicity, while reducing the cellular features of the cancer (hyperproliferation, growth, and metastasis).
This study evaluated the various selenium compounds tested, the cell lines and model organisms used, the assays performed, and the cellular pathways affected.
Examining the possible benefits of selenium in TNBC treatment highlights the need for more studies to confirm selenium compounds as viable co-therapeutic agents.
最致命、最危险的乳腺癌亚型是三阴性乳腺癌，它缺乏治疗靶点，在全球所有与乳腺癌相关的死亡病例中占30%。三阴性乳腺癌的特征是不表达雌激素、孕激素或人表皮生长因子2受体。这表明需要副作用更少的新治疗方式。
本研究的目的是研究硒化合物作为三阴性乳腺癌（TNBC）辅助治疗的潜力，无论是单独使用还是与营养补充剂和化疗药物联合使用。
使用关键词“硒”和“三阴性乳腺癌”在PubMed数据库中进行全面搜索，得到23篇文章。纳入时考虑了以下因素：使用TNBC细胞系或体内肿瘤/标本的研究；来自PubMed数据库的全文文章；以英文发表的研究；具有统计学显著结果的实验；以及单独使用硒或与其他抗氧化剂或化疗联合使用。这导致本综述评估了13篇文章。
结果表明，硒疗法增强了抗癌药物的效果并产生肿瘤细胞毒性，同时减少了癌症的细胞特征（过度增殖、生长和转移）。
本研究评估了所测试的各种硒化合物、所使用的细胞系和模式生物、所进行的检测以及受影响的细胞途径。
研究硒在TNBC治疗中的潜在益处凸显了需要更多研究来确认硒化合物作为可行的联合治疗药物。
